Is TB-500 Safe? Safety Profile 2026 — PeptidePrices

Q: Is TB-500 safe?

TB-500 has a safety rating of 6/10 in our methodology — moderate. Parent protein TB4 has Phase II data; fragment widely used anecdotally; proangiogenic concern theoretical

Q: Is TB-500 FDA approved?

FDA status: Not FDA-approved. PeptidePrices does not sell or recommend any compound for human use; this information is for research-context only.

Q: Where can I find verified TB-500?

PeptidePrices tracks live prices and COA verification status across 30+ vendors. See our cheapest TB-500 listings for prices ranked by COA tier and $/mg.

Safety Profile

TB-500

Updated today

Cellular Peptide

6/10Moderate

How we score compound safety →

Primary use: Tissue repair research

Regulatory Status

Not FDA-approved

Safety Summary

Parent protein TB4 has Phase II data
fragment widely used anecdotally
proangiogenic concern theoretical

TB-500's 6/10 rating reflects mixed evidence — some clinical data and a meaningful research base, but enough open questions that researchers should weight personal risk tolerance heavily. Long-term safety in the population segment most likely to use this compound (off-label) is the area with the thinnest published evidence. Researchers often consider BPC-157 and GHK-Cu as alternatives in the same category — see the related-compounds section below for safety comparisons.

Molecular Profile

TypeEndogenous peptide / synthetic analog

Molecular Weight4,963 Da

Amino Acids43

CAS Number77591-33-4

Storage

Lyophilized−20°C, stable long-term

Reconstituted2–8°C, 14–30 days

Protect from light
Store desiccated
Sterile handling required
Avoid repeated freeze-thaw

Related Compounds

Methodology

How we rate peptide safety

Every compound in our index gets a 1–10 safety score based on four weighted factors. The score reflects known research-use risk — not medical advice.

40% — Clinical evidence. Volume of peer-reviewed trials, sample sizes, duration, and consistency of outcomes. FDA-approved compounds anchor the top end (8–10); preclinical-only compounds cap at 6.
30% — Adverse-event profile. Severity and frequency of reported side effects, including GI events, cardiovascular signals, hypoglycemia, and long-term organ effects.
20% — Regulatory status. FDA approval, EMA approval, or status in active clinical trials. Compounds under safety warnings are penalized.
10% — Community-reported outcomes. Reddit, forum, and published case-report signal beyond formal trials. Used as a late-stage tiebreaker, not a leading factor.

9–10Well-studied, FDA-approvedLarge-trial evidence, established long-term safety. Examples: semaglutide, tesamorelin at approved doses.

7–8Mostly safe, some caveatsPhase 2/3 evidence or long community track record with known manageable side effects. Routine monitoring recommended.

5–6Mixed dataLimited clinical trials, mostly community/preclinical data. Real but uncertain risk profile.

3–4Caution advisedKnown side-effect patterns, thin safety data, or compounds under active regulatory scrutiny.

1–2Significant risk signalsDocumented serious adverse events (cardiovascular, hepatotoxicity, contamination) or withdrawn regulatory status.

Related compounds

Other compounds researchers compare with TB-500

Full TB-500 profile Cheapest TB-500 deals

Safety ratings are derived from published clinical data, FDA approval status, and community-reported outcomes. They are not medical advice. Always consult a healthcare professional before using any research compound.